Arch Biopartners Inc.

08/02/2024 | Press release | Distributed by Public on 08/02/2024 05:33

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.